Werewolf Therapeutics (HOWL) Revenue (2022 - 2026)

Werewolf Therapeutics (HOWL) posted quarterly Revenue of $21.0 million for Q2 2026, up 139900.0% on a QoQ basis from $15000.0 in Q4 2024.

Werewolf Therapeutics (HOWL) Revenue (2022 - 2026) Analysis & Trends

Werewolf Therapeutics has reported Revenue for 4 years, with the latest figure at $21.0 million in Q2 2026.

Revenue for Q2 2026 came in at $21.0 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2026 was $21.0 million (up 139900.0% YoY), and the FY2024 annual result was $1.9 million, down 90.47% from the prior year.
Revenue advanced to $21.0 million in Q2 2026, from $15000.0 in the prior quarter.
Over five years, Revenue peaked at $21.0 million in Q2 2026 and troughed at $15000.0 in Q4 2024.
A 4-year average of $5.4 million and a median of $4.5 million in 2023 frame the typical range for Revenue.
The widest annual swing landed in 2023, when Revenue soared 94.82%; it then tumbled 99.0% in 2024.
A 4-year view of Revenue shows it stood at $7.3 million in 2022, then slumped by 79.39% to $1.5 million in 2023, then tumbled by 99.0% to $15000.0 in 2024, then jumped by 139900.0% to $21.0 million in 2026.
Per Business Quant data, the three most recent Revenue figures were $21.0 million in Q2 2026, $15000.0 in Q4 2024, and $1.1 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	1.52 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	1.29 Bn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	1.06 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	425.49 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	674.14 Mn
10	Werewolf Therapeutics	43.94 Mn	43.94 Mn	-	21.00 Mn

Download Data